| Officer | Age | In this role | Source |
|---|---|---|---|
|
Matthew Roden, PhD
Also a director
President, Chief Executive Officer and Director
|
55 |
Since 2020
6 years
|
|
|
Kyle D. Kuvalanka
Chief Financial Officer
|
57 |
Since 2025
1 year
|
|
|
Shulamit Ron-Bigger, PhD
Chief Operating Officer
|
45 |
Since 2022
4 years
|
|
|
Akos Czibere, MD, PhD
Chief Medical Officer
|
48 |
Since 2024
2 years
|
|
|
Paul L. Feldman, PhD
Chief Scientific Officer
|
65 |
Since 2020
6 years
|
|
|
Tyler Benedum, PhD
Chief Technical Officer
|
50 |
Since 2024
2 years
|
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the 10-K annual report · updated by the 8-K of Apr 16, 2026
| Director | Age | On board | Committees | Other public boards | Pay | Source |
|---|---|---|---|---|---|---|
|
Todd Foley
Board chair
|
54 |
2020
6 years
|
None stated | None stated | Not stated | |
|
Matthew Roden
CEO
|
55 |
2020
6 years
|
None stated | None stated | Paid as CEO | |
|
Ken Herrmann
|
48 |
2024
2 years
|
None stated | None stated | Not stated | |
|
Lloyd M. Segal
|
62 |
2021
5 years
|
None stated | None stated | Not stated | |
|
Michael A. Sherman
|
59 |
2025
1 year
|
None stated | Werewolf Therapeutics, Inc. (Nasdaq: HOWL) | Not stated | |
|
Mary Thistle
|
66 |
2025
1 year
|
None stated | Cullinan Therapeutics, Inc. (Nasdaq: CGEM) | Not stated | |
|
Glenn Gormley
Joined Apr 15, 2026
|
- | - |
Science and Technology Committee · Chair
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Related-party transactions come from the company’s proxy statement. Aktis Oncology, Inc. has not filed one with the SEC.
Loading...